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Objectives: To investigate the prevalence and risk factors for asymptomatic toxigenic (TCD) and non-
toxigenic Clostridium difﬁcile (NTCD) colonization in a broad cross section of the general hospital pop-
ulation over a 3-year period.
Methods: Patients without diarrhoea admitted to two Australian tertiary hospitals were randomly
selected through six repeated cross-sectional surveys conducted between 2012 and 2014. Stool speci-
mens were cultured under anaerobic conditions, and C. difﬁcile isolates were tested for the presence of
toxin genes and ribotyped. Patients were then grouped into noncolonized, TCD colonized or NTCD
colonized for identifying risk factors using multinomial logistic regression models.
Results: A total of 1380 asymptomatic patients were enrolled; 76 patients (5.5%) were TCD colonized and
28 (2.0%) were NTCD colonized. There was a decreasing annual trend in TCD colonization, and asymp-
tomatic colonization was more prevalent during the summer than winter months. TCD colonization was
associated with gastro-oesophageal reﬂux disease (relative risk ratio (RRR) ¼ 2.20; 95% conﬁdence in-
terval (CI) 1.17e4.14), higher number of admissions in the previous year (RRR ¼ 1.24; 95% CI 1.10e1.39)
and antimicrobial exposure during the current admission (RRR ¼ 2.78; 95% CI 1.23e6.28). NTCD colo-
nization was associated with chronic obstructive pulmonary disease (RRR ¼ 3.88; 95% CI 1.66e9.07) and
chronic kidney failure (RRR ¼ 5.78; 95% CI 2.29e14.59). Forty-eight different ribotypes were identiﬁed,
with 014/020 (n ¼ 23), 018 (n ¼ 10) and 056 (n ¼ 6) being the most commonly isolated.
Conclusions: Risk factors differ between patients with asymptomatic colonization by toxigenic and non-
toxigenic strains. Given that morbidity is largely driven by toxigenic strains, this novel ﬁnding has
important implications for disease control and prevention. L. Furuya-Kanamori, CMI 2017;23:48.e1e48.e7
© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
Introduction
Clostridium difﬁcile infection (CDI) is the main cause of
healthcare-associated diarrhoea. Toxigenic C. difﬁcile (TCD) strains
produce toxins A and B, and, increasingly, binary toxin (CDT), which
are responsible for the clinical presentation of CDI, ranging from
mild diarrhoea to severe life-threatening conditions such as pseu-
domembranous colitis [1]. It is estimated that up to two-thirds of
patients who are exposed to C. difﬁcile remain asymptomatic [2].
There is growing evidence that asymptomatic patients colonized
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with TCD can act as a source of C. difﬁcile transmission and envi-
ronmental contamination in hospitals [3,4]. However, not all
C. difﬁcile strains produce toxins, and it has been proposed that
asymptomatic patients colonized with nontoxigenic C. difﬁcile
(NTCD) strains are protected from colonization by heterologous
strains, including toxigenic strains, as a result of niche competition
or stimulation of the mucosal immune response in the gastroin-
testinal tract [5].
Limited evidence indicates that asymptomatic colonized pa-
tients may potentially play a role in transmission [6]. The associated
host risk factors (e.g. sex, age, comorbidities and medication
exposure) and pathogen characteristics (e.g. toxigenic proﬁle and
predominant ribotypes) among this group are poorly understood
[7]. Few studies have investigated the prevalence of asymptomatic
TCD and NTCD colonization in a broad cross section of the general
hospital patient population [8], nor have the between-season
variability or temporal trends of prevalence been reported.
Therefore, a 3-year studywith biannual surveys in adult patients
was conducted in two Australian tertiary-care hospitals in different
Australian states with the following aims: to estimate the preva-
lence of asymptomatic C. difﬁcile colonization; to compare the
prevalence during summer and winter months and over time; to
describe the predominant toxin proﬁles and ribotypes isolated
from asymptomatic patients; and to identify host factors associated
with TCD and NTCD colonization.
Materials and Methods
Study setting and participants
The study was conducted in two tertiary hospitals in Australia,
the Royal Brisbane &Women's Hospital (RBWH), with 929 beds in
Brisbane, Queensland, and the Sir Charles Gairdner Hospital
(SCGH), with 607 beds in Perth, Western Australia. The patients
were prospectively recruited through six repeated cross-sectional
surveys conducted between 2012 and 2014. Each year, two sur-
veys were conducted, one starting in late summer (Februar-
yeMarch) and the other in late winter (AugusteSeptember).
On the morning of each survey day, a sampling frame of
currently admitted patients in the wards (i.e. medical, surgical,
intensive care units) to be surveyed was created in a spreadsheet,
with each patient given a unique ID. Patient IDs were drawn at
random from the spreadsheet (using a random number generator).
If the patient's ID was randomly selected, was 18 years of age or
older and did not present diarrhoea (i.e. 3 or more loose or liquid
bowel motions per day), the research nurse approached the patient
and invited him or her to participate in the study.
The study received the approval of the RBWH (HREC/11/QRBW/
223), the Sir Charles Gairdner Group (2011-088), the University of
Queensland (2011000898) and the University of Western Australia
(RA/4/1/5186) human research ethics committees. All the partici-
pants (or a legal proxy) provided written informed consent for their
inclusion in the study. InWestern Australia, awaiver of consent was
granted when a person was unable to provide consent but the
person could be enrolled onto the study without any additional risk
beyond their standard care.
Data collection
Patients were interviewed to obtain demographic data and in-
formation on known CDI risk factors (e.g. use of various medica-
tions before admission, history of CDI and hospital admissions).
Patient medical records were reviewed to determine the date and
the reason for the latest admission, recent history of diarrhoea,
comorbid conditions, inpatient medication (e.g. antimicrobials,
gastric acid suppressants, nonsteroidal anti-inﬂammatory drugs)
and medical procedures (e.g. colonoscopy, surgery) during the
admission.
If C. difﬁcilewas isolated from the patients' stool specimens, the
patients were monitored while hospitalized and followed up after
discharge on a monthly basis for 3 months. The follow-up in-
terviews were used to determine the patients' clinical outcomes
and whether they remained asymptomatic, were readmitted to a
hospital, were diagnosed with CDI, developed colitis or died.
Specimen collection and processing
Specimens from the enrolled patients were obtained using a
rectal swab from consenting patients. Stool specimens were ob-
tained from patients who were enrolled and able to provide a stool
specimen but who did not consent to provide a rectal swab.
Swabs were cultured for C. difﬁcile within 30 minutes of
collection and stool samples were cultured within 24 hours using
our previously described methods [9], except that direct culture
was performed on ChromID C. difﬁcile agar (bioMerieux, Marcy
l’Etoile, France) and plates were examined at 24 and 48 hours for
characteristic growth. Broth enrichment in Robertson cooked meat
medium containing 5 mg/L of gentamicin, 250 mg/L of cycloserine
and 8 mg/L of cefoxitin was performed concurrently and ethanol
shocked after 48 to 72 hours for subculture on ChromID agar if
direct culture was negative. Putative C. difﬁcile colonies were sub-
cultured onto prereduced blood agar plates for identiﬁcation by
characteristic colony morphology and odour, chartreuse ﬂuores-
cence under UV light and proline aminopeptidase production
(Diatabs; Rosco Diagnostica, Taastrup, Denmark) at 48 hours. All
agar plate incubations were performed at 35C under anaerobic
conditions.
C. difﬁcile isolates were tested for the presence of toxin genes
(tcdA, tcdB and cdtA/cdtB) and were polymerase chain reaction
(PCR) ribotyped following previously described methods [9].
Strains that did not produce banding patterns matching an inter-
national ribotype in the reference collection were assigned local
nomenclature (QX type).
Statistical analysis
All enrolled patients not experiencing diarrhoea who had
C. difﬁcile isolated from their stool were considered to have
asymptomatic C. difﬁcile colonization. If the strain isolated was
positive for the presence of tcdA, tcdB or cdtA/cdtB genes, then the
patient was considered asymptomatic TCD colonized; if the iso-
lated strain was negative for all toxin genes, then the patient was
considered asymptomatic NTCD colonized. Therefore, for the pur-
pose of the analyses, patients were grouped into three categories
according to their status with respect to C. difﬁcile colonization at
the time of enrolment: noncolonized, TCD colonized and NTCD
colonized. The overall and speciﬁc survey prevalence of TCD and
NTCD colonized patients were calculated.
Pearson's chi-square test and Fisher's exact test were used to
compare categorical variables, and the Kruskal-Wallis H test was
used to compare continuous variables across the three categories of
C. difﬁcile colonization. Univariate and multivariate multinomial
logistic regression models were built with C. difﬁcile colonization as
the outcome and noncolonized patients as the reference category
to identify predictors of TCD and NTCD colonized patients. After
adjusting for age and sex of the patients, known risk factors for CDI
(i.e. hospital admissions and exposure to antimicrobials), the in-
clusion of comorbidities and medication exposure during the cur-
rent admission in the regression model were analysed through a
stepwise forward selectionwith the Akaike information criterion as
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the selection criterion. A signiﬁcance level cutoff of p <0.05 was
used for all analyses. All statistical analyses were conducted by
Stata SE 14 (StataCorp, College Station, TX, USA).
Results
Prevalence of asymptomatic C. difﬁcile colonization and seasonal
variation
During the six surveys throughout the 3 years, 1380 patients
were enrolled onto the study (595 and 785 patients from the RBWH
and SCGH, respectively) (Supplementary Material 1). The median
time between the patients being admitted to hospital and enrol-
ment onto the study was 5 days (interquartile range 2e10 days),
and 25% of the patients were enrolled within 48 hours of being
admitted. There was no statistically signiﬁcant difference in time
between being admitted and enrolment for both hospitals and
across the six surveys (Supplementary Material 2).
C. difﬁcile was isolated from 104 patients (7.5%; 95% conﬁdence
interval (CI) 6.2e9.1). A higher prevalence of C. difﬁcile colonization
was observed at SCGH (9.8%; 95% CI 7.8e12.1) compared to RBWH
(4.5%; 95% CI 3.0e6.5). Among the enrolled patients, 76 (5.5%; 95%
CI 4.4e6.8) and 28 (2.0%; 95% CI 1.4e2.9) were colonized with TCD
and NTCD strains, respectively. A higher prevalence of asymptom-
atic C. difﬁcile colonization was observed during the summer sur-
veys (8.8%; 95% CI 6.9e11.1) compared to the winter surveys (5.9%;
95% CI 4.2e8.1) (Fig. 1). The prevalence of asymptomatic C. difﬁcile
colonization was highest during the ﬁrst survey (FebruaryeMarch
2012), when 33 out of 294 patients were colonized (11.2%; 95% CI
7.9e15.4), including 28 (9.5%; 95% CI 6.4e13.5) patients colonized
with TCD strains. The lowest prevalence was observed during the
fourth survey (AugusteSeptember 2013); C. difﬁcile was isolated
from 14 (5.6%; 95% CI 3.1e9.2) patients among the 250 patients
enrolled during that survey. The seasonal patterns were similar in
both hospitals.
Characterization of C. difﬁcile
Among the 104 C. difﬁcile isolates, ﬁve toxin proﬁles were
identiﬁed, with AþBþCDT being the most common (n¼ 71, 68.3%).
Three isolates (2.9%) were AþBþCDTþ, one (1.0%) was A-BþCDT,
one (1.0%) was ABCDTþ and the remaining 28 isolates (26.9%)
were ABCDT. Forty-eight different ribotypes were identiﬁed;
the most common ribotype was the 014/020 group (n ¼ 23, 22.1%),
followed by 018 (n ¼ 10, 9.6%), 056 (n ¼ 6, 5.8%), 010 (n ¼ 5, 4.8%)
and 103 (n ¼ 5, 4.8%). The four binary toxinepositive isolates were
PCR ribotypes 063, 127, 251 and QX 220 (Fig. 2, Supplementary
Material 3).
Predictors of toxigenic and nontoxigenic C. difﬁcile colonization
The characteristics of patients enrolled onto the study are
described in Table 1. There were no differences between non-
colonized, TCD colonized and NTCD colonized patients in terms of
sex proportion or mean age. Among the comorbidities, cancer
prevalence was less common among NTCD colonized patients (7.1%
vs. 34.7% (noncolonized) vs. 29.7% (TCD)). Gastro-oesophageal
reﬂux disease and congestive heart failure were more prevalent
among TCD colonized patients, while chronic obstructive pulmo-
nary disease and chronic kidney disease were more prevalent
among NTCD colonized patients. Five (0.4%), three (4.0%) and two
(7.1%) noncolonized, TCD colonized and NTCD colonized patients,
respectively, reported having a history of CDI. With regards to
healthcare exposure, 64% of TCD and NTCD colonized patients had
been admitted to hospital at least once in the previous year
compared to 46% of noncolonized patients.
The reasons for the current admission did not signiﬁcantly differ
between the three C. difﬁcile colonization categories (Table 2).
Exposure to antimicrobials during the admission was common
among all the patients; however, it was signiﬁcantly higher in TCD
(83.8%) and NTCD colonized patients (78.6%) compared to non-
colonized patients (66.4%; p 0.004). There were no differences in
other medication exposure (gastric acid suppressants, aperients,
nonsteroidal anti-inﬂammatory drugs, glucocorticoids, chemo-
therapy or antidiarrhoeals) or medical procedures (insertion of
orogastric tube, gastroscopy, colonoscopy ormechanical ventilation)
during the admission across the colonization categories. In terms of
surgical procedures, a signiﬁcantly higher proportion of TCD colo-
nized patients underwent orthopaedic (25.0%) and neurologic
(14.5%) surgeries compared to noncolonized patients (12.9% ortho-
paedic and 5.6% neurologic) and NTCD colonized patients (10.7%
orthopaedic and 3.6% neurologic) (p 0.016 and 0.013, respectively).
In the multivariate multinomial logistic regression model, fac-
tors associated with an increased relative risk ratio (RRR) of har-
bouring a TCD strain compared to noncolonized included having
gastro-oesophageal reﬂux disease (RRR 2.20; 95% CI 1.17e4.14),
number of hospital admissions in the previous year (RRR 1.24; 95%
CI 1.10e1.39), exposure to antimicrobials during the period of
Fig. 1. (a) Seasonal variation of Clostridium difﬁcile colonization prevalence and (b) variation by toxigenic proﬁle. Green triangles, blue squares and red circles represent prevalence
of overall, toxigenic and nontoxigenic C. difﬁcile colonization, respectively. Vertical lines represent 95% conﬁdence interval around prevalence estimates.
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admission (RRR 2.78; 95% CI 1.23e6.28) and admission during the
summer months (RRR 1.81; 95% CI 1.07e3.06) (Table 3). The
regression model also revealed a decreasing annual trend in TCD
colonization prevalence (RRR 0.68; 95% CI 0.47e0.97). For har-
bouring a NTCD strain relative to noncolonized, having chronic
obstructive pulmonary disease (RRR 3.88; 95% CI 1.66e9.07) and
chronic kidney failure (RRR 5.78; 95% CI 2.29e14.59) were associ-
ated with an increased RRR.
Over the 3-month follow-up, ﬁve colonized patients (4 (5.3%)
TCD and 1 (3.6%) NTCD) reported developing CDI, and there were
Fig. 2. Distribution of ribotypes among Clostridium difﬁcile colonized patients. Blue and red bars represent frequency of toxigenic and nontoxigenic C. difﬁcile strains isolated in
study, respectively. Ribotypes with toxin proﬁle of AþBþCDT and ABCDT and frequency of two or fewer were grouped into “other.”
Table 1
Patient characteristics
Characteristic Noncolonized (n ¼ 1276) Toxigenic Clostridium
difﬁcile (n ¼ 76)
Nontoxigenic Clostridium
difﬁcile (n ¼ 28)
pa
Female sex 600 (47.0%) 40 (52.6%) 13 (46.4%) 0.633
Age, years, mean (SD) 61.8 (17.4) 64.1 (16.1) 64.3 (20.96) 0.414
Medical condition
Cancer 441 (34.7%) 22 (29.7%) 2 (7.1%) 0.003
Diabetes mellitus 297 (23.4%) 18 (24.3%) 8 (28.6%) 0.806
Neurologic disorder 283 (22.3%) 23 (31.1%) 8 (28.6%) 0.165
GORD 256 (20.1%) 24 (32.4%) 7 (25.0%) 0.035
COPD 218 (17.2%) 17 (23.0%) 11 (38.3%) 0.005
Chronic kidney disease 107 (8.4%) 14 (18.9%) 9 (32.1%) <0.001
Congestive heart failure 98 (7.7%) 12 (16.2%) 3 (10.7%) 0.029
Liver disease 90 (7.1%) 4 (5.4%) 2 (7.1%) 0.896
Inﬂammatory bowel disease 53 (4.2%) 3 (4.1%) 2 (7.1%) 0.578
Pregnancy 24 (1.9%) 0 (0.0%) 1 (3.6%) 0.384
Solid organ transplant 21 (1.7%) 1 (1.4%) 2 (7.1%) 0.118
HIV 5 (0.4%) 0 (0.0%) 0 (0.0%) 1.000
Smoking status
Current 171 (13.4%) 7 (9.3%) 1 (3.6%) 0.218
Ever 754 (59.2%) 43 (58.1%) 13 (46.4%) 0.391
History of CDI (ever) 5 (0.4%) 3 (4.0%) 2 (7.1%) <0.001
History of CDI in the last year 1 (0.1%) 0 (0.0%) 2 (7.1%) 0.002
Healthcare exposure 12 months before admission
Admitted to hospital 584 (46.4%) 47 (64.4%) 18 (64.3%) 0.002
No. of admissions, median (IQR) 0 (0e2) 1 (0e3) 2 (0e3) <0.001
LOS in the last admission, median (IQR) 4 (1e9) 6 (3e9) 8 (3e17) 0.997
Medication exposure 30 days before admission
Antimicrobials 770 (63.4%) 51 (69.9%) 17 (60.7%) 0.506
Gastric acid suppressants 550 (44.5%) 29 (40.3%) 11 (39.3%) 0.685
Aperients 479 (43.4%) 29 (51.8%) 12 (46.2%) 0.453
CDI, Clostridium difﬁcile infection; COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reﬂux disease; IQR, interquartile range; LOS, length of stay.
a p for comparison across noncolonized, toxigenic C. difﬁcile and nontoxigenic C. difﬁcile.
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ﬁve deaths (4 (5.3%) TCD and 1 (3.6%) NTCD) not related to CDI.
Given the small number of events, no statistical analysis was
possible to compare the clinical outcomes of TCD and NTCD strains.
Discussion
The current study identiﬁed an asymptomatic C. difﬁcile colo-
nization prevalence of 7.5% across all hospital care wards, which
was signiﬁcantly lower than estimates recently reported in the
United Kingdom (11%) [10] and the United States (21%) [11]. Like-
wise, the TCD colonization prevalence (5.5%) was lower compared
to the pooled prevalence reported in a meta-analysis by Zachar-
ioudakis et al. [8] (8.1% (95% CI 5.7e11.1) worldwide and 10.0% (95%
CI 7.1e13.4) in North America). The prevalence of NTCD colonized
patients in our study (2.0%) was signiﬁcantly lower than that re-
ported by Alasmari et al. (5.8%) [11], yet the ratios between non-
toxigenic and toxigenic strains were similar in both studies (1:2.7).
Inpatient hospital transfer has been identiﬁed as an important
vehicle of C. difﬁcile (symptomatic and asymptomatic) spread
[12,13]. Given that hospital transfers in Australia mainly occur
within a circumscribed health service area (http://www0.health.
nsw.gov.au/policies/pd/2011/pdf/PD2011_031.pdf), the spread of
any infectious disease may be limited and may contribute to the
observed low prevalence of C. difﬁcile colonization in our study.
Australia's low population density might also contribute to less
intense transmission in the community [14].
Notably, ﬁndings from this study conducted in two Australian
cities located in a temperate climate zone suggest that asymptom-
atic C. difﬁcile colonization has decreased from 2012 to 2014. In
addition, it was noted that asymptomatic C. difﬁcile colonization and
symptomatic CDI displayed a synchronous seasonal trend, with
higher prevalence during summer compared to winter months
[15e19]. Understanding asymptomatic C. difﬁcile seasonality is
important because well-timed preventive and control measures
targeting patients at high risk of asymptomatic colonization can be
put in place to reduce transmission and emergence of new CDI cases.
Forty-eight different ribotypes were identiﬁed among the 104
asymptomatically colonized patients. Similar to the ﬁndings of
Table 2
Medication exposure and procedures during admission
Characteristic Noncolonized
(n ¼ 1276)
Toxigenic Clostridium
difﬁcile (n ¼ 76)
Nontoxigenic Clostridium
difﬁcile (n ¼ 28)
pa
Reason for admission
New medical/surgical problem 460 (36.8%) 35 (47.3%) 11 (39.3%) 0.175
Exacerbation of chronic condition 392 (31.4%) 19 (25.7%) 6 (21.4%)
Infection 208 (16.7%) 12 (16.2%) 10 (35.7%)
Elective surgery 171 (13.7%) 8 (10.8%) 1 (3.6%)
Obstetric condition 18 (1.4%) 0 (0.0%) 0 (0.0%)
Current length of stay, days, median (IQR)b 5 (2e10) 7 (4e17) 4 (2e8) 0.974
Medication exposure
Any antimicrobial 836 (66.4%) 62 (83.8%) 22 (78.6%) 0.004
Cephalosporins 416 (32.6%) 34 (44.7%) 9 (32.1%) 0.092
Penicillins and b-lactamase inhibitors 377 (29.6%) 21 (27.6%) 13 (46.4%) 0.141
Penicillins 186 (14.6%) 12 (15.8%) 3 (10.7%) 0.866
Vancomycin 117 (9.2%) 12 (15.8%) 4 (14.3%) 0.095
Metronidazole 106 (8.3%) 16 (21.1%) 5 (17.9%) <0.001
Macrolides 95 (7.5%) 3 (4.0%) 4 (14.3%) 0.174
Trimethoprim/sulfamethoxazole 75 (5.9%) 6 (7.9%) 3 (10.7%) 0.287
Ciproﬂoxacin 75 (5.9%) 5 (6.6%) 2 (7.1%) 0.770
Aminoglycosides 55 (4.3%) 5 (6.6%) 2 (7.1%) 0.340
Carbapenems 44 (3.5%) 6 (7.9%) 1 (3.6%) 0.114
Fluoroquinolonesc 32 (2.5%) 3 (4.0%) 1 (3.6%) 0.448
Clindamycin 29 (2.3%) 4 (5.3%) 0 (0.0%) 0.233
Tetracyclines 22 (1.7%) 0 (0.0%) 2 (7.1%) 0.093
Other antimicrobials 33 (2.6%) 2 (2.6%) 0 (0.0%) 1.000
Gastric acid suppressants 686 (54.4%) 50 (67.6%) 16 (57.1%) 0.086
Proton pump inhibitors 643 (51.0%) 46 (62.2%) 16 (57.1%) 0.150
H2 blocker 75 (5.9%) 6 (7.9%) 1 (3.6%) 0.672
Aperients 590 (46.8%) 45 (60.8%) 15 (53.6%) 0.202
NSAIDs 382 (30.4%) 19 (26.0%) 12 (42.9%) 0.593
Glucocorticoids 331 (26.3%) 23 (31.1%) 7 (25.0%) 0.654
Chemotherapy 85 (6.8%) 2 (2.7%) 1 (3.6%) 0.406
Antidiarrhoeal 29 (2.3%) 3 (4.1%) 3 (10.7%) 0.080
Medical procedures
Insertion of orogastric tubes 124 (9.8%) 8 (10.8%) 2 (7.1%) 0.885
Gastroscopy 81 (6.4%) 4 (5.4%) 2 (7.1%) 0.886
Colonoscopy 40 (3.2%) 1 (1.4%) 0 (0.0%) 0.780
Mechanical ventilationd 86 (6.8%) 10 (13.5%) 1 (3.6%) 0.158
Surgical procedures
Orthopaedic 165 (12.9%) 19 (25.0%) 3 (10.7%) 0.016
Abdominal 137 (10.7%) 6 (7.9%) 1 (3.6%) 0.480
Cardiologic/thoracic 120 (9.4%) 4 (5.3%) 2 (7.1%) 0.499
Neurologic 72 (5.6%) 11 (14.5%) 1 (3.6%) 0.013
Oncologic 36 (2.8%) 0 (0.0%) 0 (0.0%) 0.381
Other surgical procedures 121 (9.5%) 5 (6.6%) 1 (3.6%) 0.571
IQR, interquartile range; NSAID, nonsteroidal anti-inﬂammatory drug.
a p for comparison across noncolonized, toxigenic C. difﬁcile and nontoxigenic C. difﬁcile.
b Time between admission and patient enrolment.
c Ciproﬂoxacin not included.
d Excludes mechanical ventilation during surgical procedures.
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Alasmari et al. [11] in the United States, our study found that the
014/020 group was the most common ribotype among asymp-
tomatically colonized patients. However, none of the other ribo-
types reported by Alasmari et al. (012, 053, 077 and 027) was
identiﬁed among the colonized patients in Australia. The diversity
of ribotypes identiﬁed in our study corresponds with surveillance
studies among symptomatic CDI cases in hospitals in Queensland
[20] and Western Australia [9]. Furthermore, the predominant
ribotypes among symptomatic patients (014/020 group and 056) in
the surveillance studies matches our ﬁndings in asymptomatic
patients. These ﬁndings suggest that patients colonized with
C. difﬁcile may act as a source of transmission in the hospital for
new CDI cases [3,4,21].
Our study corroborates data reporting that recent hospital
admission increases the risk of TCD [2,4,8,22e24]. For each
admission to a hospital in the previous 12 months, we found that
the risk of TCD colonization increased by 24%. Gastro-oesophageal
reﬂux disease was also associated with TCD; conversely, exposure
to proton pump inhibitors (PPIs) during the admission was not a
signiﬁcant factor. Interestingly, medication exposure as a risk factor
for TCD colonization remains uncertain. Our ﬁndings align with
those reported by Kong et al. [23], who found no association be-
tween PPIs and TCD colonization; however, other studies have
identiﬁed exposure to PPIs as a risk factor for asymptomatic
C. difﬁcile colonization [24,25]. Likewise, exposure to antimicrobials
during the admission was associated with an increased risk of TCD,
while previous studies found that TCD was instead associated with
immunosuppressant use [23,24].
With regards to colonization by NTCD, a positive associationwas
observedwith chronic obstructive pulmonary disease (but not with
smoking history). Chronic renal disease has been previously re-
ported as a risk factor for TCD colonization [22,24], yet from our
study ﬁndings, chronic renal disease was only associated with
NTCD colonization. There is evidence that suggests that coloniza-
tion with NTCD is protective against infection with TCD strains;
hence, it is important to identify this group of patients and prevent
the disruption of their “naturally” protected gut microbiome
against TCD strains through the use of antimicrobials. Faecal
microbiota transplantation has proven to be a highly effective
therapeutic alternative for recurrent CDI; thus, future studies need
to investigate the potential additional beneﬁts of NTCD colonized
donors compared to noncolonized donors.
Screening all inpatients without symptoms of diarrhoea for
C. difﬁcilewill not be a cost-effective disease control measure; thus,
by understanding the risk factors, resources could be allocated to
those patients who are at high risk of being colonized by a TCD
strain. Now that Longtin et al. [26] have reported that infection
control measures (i.e. isolation precautions and environmental
control) targeting asymptomatic TCD colonized patients signiﬁ-
cantly reduces the incidence of healthcare-associated CDI, identi-
ﬁcation of risk factors becomes crucial for screening patients at
high risk of TCD colonization and allocating resources to reduce CDI
transmission in the hospitals.
A striking ﬁnding of this studywas that TCD and NTCD colonized
patients did not share risk factors. This ﬁnding may suggest that
colonization by TCD and NTCD strains are two different conditions.
TCD colonization is likely more closely related to symptomatic CDI
than NTCD colonization, given the fact that TCD colonized patients
and CDI patients (and not NTCD colonized patients) share exposure
to antimicrobials as their main risk factor.
We acknowledge that the study is limited by a number of
factors. First, given the small number of events (new CDI cases and
deaths) recorded during the follow-up period, it was not possible
to elucidate patient and strain characteristics associated with
clinical outcomes. Second, the majority of the specimens were
collected using rectal swabs (84.3%). The positivity rate with rectal
swabs was lower (6.79%) than with stool samples (11.52%), which
could have inﬂuenced the low prevalence of asymptomatic
C. difﬁcile colonization identiﬁed in this study. However, collection
of stool specimens was less convenient and less appealing to pa-
tients and would have negatively affected recruitment. Of further
note is the fact that rectal swabs were guaranteed to be collected,
as they were taken at the time of recruitment. Finally, the study
was not designed to capture when a patient was exposed to
C. difﬁcile; thus, our study population may contain patients that
acquired C. difﬁcile in the community or in the hospital. Future
studies need to investigate if community- and healthcare-
associated asymptomatic colonized patients have different
epidemiologic proﬁles as has been reported for symptomatic
community- and healthcare-associated CDI cases.
Table 3
Multinomial logistic regression models for predictors of toxigenic and nontoxigenic Clostridium difﬁcile colonization
Characteristic Toxigenic C. difﬁcile Nontoxigenic C. difﬁcile
Univariate
model, RRR (95% CI)
Multivariate
model, RRR (95% CI)
Univariate model,
RRR (95% CI)
Multivariate model,
RRR (95% CI)
Female 1.25 (0.79e1.99) 1.33 (0.76e2.33) 0.98 (0.46e2.07) 0.82 (0.37e1.82)
Age (per decade) 1.08 (0.94e1.24) 1.07 (0.90e1.28) 1.09 (0.87e1.34) 0.99 (0.78e1.25)
Medical conditions
Diabetes mellitus 1.06 (0.61e1.83) 1.26 (0.67e2.36) 1.31 (0.57e3.02) 0.96 (0.39e2.36)
Neurologic disorder 1.57 (0.95e2.62) 1.73 (0.94e3.17) 1.40 (0.61e3.20) 1.19 (0.49e2.87)
GORD 1.90 (1.15e3.16) 2.20 (1.17e4.14) 1.32 (0.56e3.14) 1.43 (0.54e3.73)
COPD 1.44 (0.82e2.52) 0.87 (0.42e1.80) 3.13 (1.44e6.77) 3.88 (1.66e9.07)
Chronic kidney disease 2.54 (1.37e4.69) 1.77 (0.83e3.75) 5.15 (2.28e11.67) 5.78 (2.29e14.59)
No. of admissions in year 1.25 (1.13e1.38) 1.24 (1.10e1.39) 1.24 (1.06e1.44) 1.14 (0.96e1.36)
Antimicrobial exposure
30 days before admission
1.34 (0.80e2.24) 0.95 (0.50e1.81) 0.90 (0.42e1.93) 0.60 (0.25e1.46)
Length of stay during
current admission
0.99 (0.98e1.01) 1.00 (0.97e1.02) 0.99 (0.98e1.01) 1.00 (0.99e1.02)
Medications during admission
Antimicrobials 2.62 (1.40e4.92) 2.78 (1.23e6.28) 1.86 (0.75e4.62) 2.40 (0.88e6.61)
Proton pump inhibitors 1.58 (0.97e2.55) 0.92 (0.50e1.72) 1.28 (0.60e2.73) 0.76 (0.31e1.82)
H2 blocker 1.39 (0.59e3.32) 1.14 (0.33e3.93) 0.58 (0.08e4.37) 0.70 (0.09e5.63)
Glucocorticoids 1.26 (0.76e2.10) 1.48 (0.82e2.66) 0.93 (0.39e2.22) 0.76 (0.30e1.93)
Year 0.78 (0.58e1.05) 0.68 (0.47e0.97) 0.94 (0.59e1.50) 0.84 (0.52e1.37)
Seasondsummer 1.73 (1.06e2.82) 1.81 (1.07e3.06) 1.13 (0.53e2.41) 1.25 (0.57e2.76)
CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; GORD, gastro-oesophageal reﬂux disease; RRR, relative risk ratio.
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One major strength of the current study was the number of
enrolled patients. This is the ﬁrst studywith a sufﬁcient sample size
to determine independent (adjusted) risk factors separately for
asymptomatic TCD and NTCD colonization. Additionally, given the
long study period, ours is the ﬁrst study to report seasonal differ-
ences in asymptomatic carriage over multiple years. Finally, it
examined not only factors associated with asymptomatic coloni-
zation before hospital admission but also included factors to which
patients were exposed during the admission, such as medical
procedures (e.g. insertion of nasogastric tubes), surgical procedures
and a detailed record of medication exposure, as well as after
hospital discharge.
In conclusion, our study found a lower prevalence of asymp-
tomatic TCD and NTCD colonized patients compared to previous
studies elsewhere. It also found that risk factors for TCD and NTCD
colonization were distinct from each other and that the prevalence
of asymptomatic carriage was seasonal, indicating that carriage in
the population is dynamic. Additional research is required to
elucidate if current international guideline recommendations of
not routinely screening and not providing treatment to asymp-
tomatic colonized patients are still the best approach.
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